Can-Fite BioPharma (CANF) said Monday that the first patient has been dosed in its phase 2a trial of Namodenoson in patients with advanced pancreatic adenocarcinoma.
The company said it targets to enroll about 20 evaluable patients in the trial.
The study's primary objective is to characterize Namodenoson's safety profile, while the secondary objective is to evaluate clinical activity using overall response rate, overall survival, and progression-free survival, among others, Can-Fite added.
Price: 2.7500, Change: -0.07, Percent Change: -2.48
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments